Apontis Pharma AG

Chart & performance

D1W1MN

P/E

121.59

P/S

1.89

EPS

0.09

Div yield, %

—

Shrs. gr., 5y

-0.40%

Rev. gr., 5y

3.90%

Revenues

48m

+31.12%

Net income

754k

CFO

-3m

L-76.98%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Operating within Germany, Apontis Pharma AG specializes in the marketing and distribution of pharmaceutical products, with a particular emphasis on internal medicine. The company is actively involved in the development, promotion, and commercialization of a diverse portfolio, which includes combination single-pill therapies and other medications. Key therapeutic areas of focus encompass cardiovascular diseases, such as high blood pressure (hypertension), elevated cholesterol (hyperlipidemia), and strategies for secondary prevention, in addition to respiratory ailments and diabetes. Established in 1946, Apontis Pharma AG maintains its corporate headquarters in Monheim am Rhein, Germany.

URL

https://www.apontis-pharma.de

IPO date

May 11, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT